Hospital
Hospital Service District 1 of East Baton Rouge Parish
Hospital Service District 1 of East Baton Rouge Parish was paid $10.10M by Medicaid between Jan 2018 and Dec 2024, across 132 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoHOSPITAL SERVICE DISTRICT 1 OF EAST BATON ROUGE PARISH
ZACHARY, LA 70791
ZACHARY, LA 70791
33aNPI1376591941assigned 05/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.10M
24GClaims429,953
24DCodes billed132
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#36 of 96
Median peer was paid$5.17M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 47,231 | $1.02M | |
| 2019 | 48,659 | $935K | |
| 2020 | 43,154 | $924K | |
| 2021 | 65,673 | $1.70M | |
| 2022 | 79,169 | $2.09M | |
| 2023 | 90,386 | $2.10M | |
| 2024incomplete | 55,681 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 30,074 | 26,531 | $2.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 11,118 | 9,693 | $1.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 16,590 | 14,859 | $1.02M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.0% | 3,084 | 1,224 | $407K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.9% | 1,437 | 1,114 | $399K |
| 80053 | Comprehensive metabolic panel | 3.1% | 44,426 | 38,264 | $310K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 13,413 | 10,605 | $306K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 47,696 | 40,256 | $244K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.3% | 1,141 | 634 | $231K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 9,475 | 6,818 | $207K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 11,765 | 10,068 | $191K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 9,737 | 7,163 | $171K |
120 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.7% | 5,499 | $170K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 5,535 | $170K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.6% | 786 | $166K |
| 87428 | 1.5% | 4,819 | $148K | |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 69,391 | $142K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.4% | 4,575 | $139K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 8,493 | $136K |
| 80061 | Lipid panel | 1.3% | 11,882 | $128K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 3,149 | $127K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.1% | 265 | $110K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,357 | $89K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 864 | $71K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 626 | $65K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 297 | $61K |
| 84484 | <1% | 8,662 | $59K | |
| 84703 | <1% | 8,711 | $50K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,208 | $49K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,401 | $46K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,774 | $44K |
| 81001 | <1% | 19,593 | $41K | |
| 80050 | General health panel | <1% | 1,077 | $41K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,136 | $39K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 84 | $37K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 856 | $34K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,678 | $34K |
| 83735 | <1% | 7,772 | $31K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,007 | $24K |
| 97597 | <1% | 1,673 | $21K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 103 | $21K |
| 81514 | <1% | 156 | $19K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 931 | $18K |
| 83880 | <1% | 867 | $15K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 444 | $15K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 243 | $14K |
| 86803 | <1% | 1,074 | $13K | |
| 83690 | <1% | 2,828 | $13K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 940 | $12K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 285 | $11K |
| 84403 | <1% | 482 | $10K | |
| 82553 | <1% | 1,775 | $10K | |
| 87486 | <1% | 253 | $10K | |
| 87581 | <1% | 253 | $10K | |
| 86592 | <1% | 2,504 | $9K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 223 | $9K |
| 87340 | <1% | 942 | $8K | |
| 82550 | <1% | 2,030 | $7K | |
| 0001A | <1% | 325 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 911 | $6K |
| 83615 | <1% | 1,783 | $6K | |
| 0002A | <1% | 318 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 917 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 35 | $6K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 404 | $5K |
| 84439 | <1% | 656 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,921 | $4K |
| 80076 | <1% | 605 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 127 | $3K |
| 87081 | <1% | 604 | $3K | |
| 83605 | <1% | 525 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 75 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 184 | $2K |
| 81025 | <1% | 438 | $2K | |
| 86696 | <1% | 72 | $2K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 443 | $2K |
| 84153 | <1% | 119 | $2K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 1,216 | $2K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 53 | $1K |
| 81003 | <1% | 1,005 | $1K | |
| 86695 | <1% | 72 | $1K | |
| 87481 | <1% | 41 | $1K | |
| 86701 | <1% | 127 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,772 | $1K |
| 87210 | <1% | 258 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 443 | $988.40 |
| 80081 | <1% | 17 | $973.18 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17 | $799.20 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,625 | $779.59 |
| 82077 | <1% | 85 | $725.20 | |
| 80143 | <1% | 42 | $531.24 | |
| 80179 | <1% | 41 | $517.26 | |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $471.24 |
| 87150 | <1% | 15 | $421.08 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 13 | $416.04 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 96 | $393.09 |
| 86140 | <1% | 113 | $336.70 | |
| 87077 | <1% | 39 | $313.13 | |
| 83655 | <1% | 26 | $309.10 | |
| 82728 | <1% | 25 | $299.86 | |
| 85027 | <1% | 45 | $291.15 | |
| 87040 | <1% | 35 | $268.32 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 469 | $238.55 |
| 80320 | <1% | 370 | $215.36 | |
| 83550 | <1% | 25 | $192.28 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,494 | $187.46 |
| 85379 | <1% | 13 | $111.98 | |
| 86708 | <1% | 14 | $111.51 | |
| 17250 | <1% | 14 | $107.36 | |
| 88342 | <1% | 94 | $99.68 | |
| 85610 | <1% | 33 | $85.80 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24 | $70.49 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 200 | $68.97 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 36 | $65.32 |
| 82962 | <1% | 124 | $57.08 | |
| 82043 | <1% | 14 | $52.02 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 77 | $37.19 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 71 | $31.13 |
| 85730 | <1% | 18 | $30.05 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 21 | $14.82 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $11.71 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 16 | $9.74 |
| 99156 | <1% | 2,627 | $7.87 | |
| 91300 | <1% | 426 | $4.19 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 108 | $2.46 |
| 99157 | 0% | 1,505 | $0.00 | |
| 99152 | 0% | 251 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 525 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 154 | $0.00 |
| 00000 | 0% | 27 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHACKER, PHIL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Hospital Service District 1 of East Baton Rouge Parish | Zachary, LA | $154K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.